KPV vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | KPV | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 200 mcg–500 mcg | 20 mg–40 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
KPV, SS-31 (Elamipretide) are both commonly used for:
Key Differences
Unique to KPV:
Unique to SS-31 (Elamipretide):
Which Has Stronger Evidence?
- Recovery & Healing: SS-31 (Elamipretide) has stronger research support.
| Goal | KPV | SS-31 (Elamipretide) |
|---|---|---|
| Recovery & Healing | low | medium |
Key Studies
KPV
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.
Tissue & cell, 2026
- KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
Advanced healthcare materials, 2024
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.
Acta biomaterialia, 2022
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?